Skip to main content

There was much excitement at the latest ASCENT ASD Investigators’ meeting in Chicago (IL). Implanting teams from several US centers met for the first time since the trial reached its pivotal phase.

ASCENT ASD Trial Status

“For some of us early implanters, it feels like the trial is coming of age, with over 75 patients implanted across two continents,” said Thomas Forbes, MD, now Chief Pediatric Cardiac Services, Joe DiMaggio Children’s Hospital (Hollywood, FL). He performed one of the first implants at trial initiation, in his original role as Director of Cardiac Catheterization Laboratory at Children’s Hospital of Michigan (Detroit, MI). “We know the device, we work closely with the atHeart team and the other implanting sites and we are all observing the device on an ongoing basis in our patients, as part of the follow-up process.”

The ASCENT ASD trial is a US FDA and French ANSM-approved clinical study to assess the safety and efficacy of the reSept ASD occluder. reSept is the first transcatheter septal occluder with a metal-free frame. The trial is currently enrolling patients in over 20 study centers in the United States and in France.


“A device that enables a conservative management of the septum may be the difference between requiring or avoiding open-heart surgery in someone’s life, in case for instance of heart valve repair at a later age,” said Larry Latson, MD, the US National Principal Investigator for the ASCENT ASD study and a pediatric and adult cardiologist at Joe Dimaggio Children’s Hospital (Hollywood, FL). “Even though pediatric patients may most likely have a different treating clinician in adult life, making long-term decisions early on is very important”.

An atrial septal defect is a hole in the heart wall that separates the two upper heart chambers called atria. ASDs are among the most common heart defects children may be born with. Please follow the link for further information on ASDs.